menu
    • menu
    [{"orgOrder":0,"company":"CellResearch Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"CellResearch Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellResearch Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CellResearch Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Podiatry","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BAY1193397","moa":"Adrenergic receptor alpha-2C (ADRA2C)","graph1":"Podiatry","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Contezolid Acefosamil","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase III","graph3":"MicuRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MicuRx \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Contezolid Acefosamil","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"MicuRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Royer Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Royer Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Royer Biomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Royer Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase III","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase III","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Private Placement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Murdoch Children\u2019s Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"R327","moa":"Bacterial cell wall synthesis","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Ertapenem","moa":"Bacterial penicillin-binding protein","graph1":"Podiatry","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-1 adrenergic receptor | Beta-2 adrenergic receptor","graph1":"Podiatry","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"NovaLead Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-1 adrenergic receptor | Beta-2 adrenergic receptor","graph1":"Podiatry","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaLead Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"VA Northern California Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Podiatry","graph2":"Phase III","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ VA Northern California Health Care System","highestDevelopmentStatusID":"10","companyTruncated":"VA Office of Research and Development \/ VA Northern California Health Care System"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Podiatry","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Innocan Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Cell membrane||Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lakewood-Amedex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Undisclosed"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Cell membrane||Cell membrane structures","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lakewood-Amedex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Undisclosed"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Professional Education and Research Institute | PrimeVigilance Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lakewood-Amedex \/ Professional Education and Research Institute | PrimeVigilance Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Professional Education and Research Institute | PrimeVigilance Ltd"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lakewood-Amedex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Undisclosed"},{"orgOrder":0,"company":"Clinical Alliance for Research & Education - Infectious Diseases, LLC.","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Daptomycin","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase IV","graph3":"Clinical Alliance for Research & Education - Infectious Diseases, LLC.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Alliance for Research & Education - Infectious Diseases, LLC. \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Clinical Alliance for Research & Education - Infectious Diseases, LLC. \/ Merck & Co"},{"orgOrder":0,"company":"Dipexium Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Cytolex","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase III","graph3":"Dipexium Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dipexium Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dipexium Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dipexium Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Cytolex","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase III","graph3":"Dipexium Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dipexium Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dipexium Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Best Buy Medical Canada","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Best Buy Medical Canada","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Best Buy Medical Canada"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"BioStem Technologies","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ BioStem Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ BioStem Technologies"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Qatar Datamation Systems","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Qatar Datamation Systems","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Qatar Datamation Systems"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"SMITH & NEPHEW INC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SMITH & NEPHEW INC \/ Undisclosed"},{"orgOrder":0,"company":"Orkla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Podiatry","graph2":"Undisclosed","graph3":"Orkla","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Orkla \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Orkla \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HTX-034","moa":"COX-2","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institutes of Health | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Plerixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Podiatry","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Institutes of Health | Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ National Institutes of Health | Sanofi"},{"orgOrder":0,"company":"Bridge BioResearch","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Podiatry","graph2":"Phase II","graph3":"Bridge BioResearch","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bridge BioResearch \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bridge BioResearch \/ Undisclosed"},{"orgOrder":0,"company":"Technophage","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"TP-102","moa":"Enzymes","graph1":"Podiatry","graph2":"Phase II","graph3":"Technophage","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Technophage \/ VectorB2B","highestDevelopmentStatusID":"8","companyTruncated":"Technophage \/ VectorB2B"},{"orgOrder":0,"company":"Technophage","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"TP-102","moa":"Enzymes","graph1":"Podiatry","graph2":"Phase II","graph3":"Technophage","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Technophage \/ VectorB2B","highestDevelopmentStatusID":"8","companyTruncated":"Technophage \/ VectorB2B"},{"orgOrder":0,"company":"Remedor Biomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Remedor Biomed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Remedor Biomed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Remedor Biomed \/ Undisclosed"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Karyopharm Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Xbiome","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"AUP-16","moa":"FGF2","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Aurealis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurealis Therapeutics \/ Xbiome","highestDevelopmentStatusID":"7","companyTruncated":"Aurealis Therapeutics \/ Xbiome"},{"orgOrder":0,"company":"Olympus Biotech Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Trafermin","moa":"Fibroblast growth factor receptor 2","graph1":"Podiatry","graph2":"Phase III","graph3":"Olympus Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Olympus Biotech Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Olympus Biotech Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Olympus Biotech Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Trafermin","moa":"Fibroblast growth factor receptor 2","graph1":"Podiatry","graph2":"Phase III","graph3":"Olympus Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Olympus Biotech Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Olympus Biotech Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Butylated Hydroxyanisole","moa":"Free radical","graph1":"Podiatry","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biotechnology Institute IMASD","sponsor":"Hospital de Basurto","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"MEXICO","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Plasma Rich In Growth Factors","moa":"Growth factor","graph1":"Podiatry","graph2":"Phase IV","graph3":"Biotechnology Institute IMASD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotechnology Institute IMASD \/ Hospital de Basurto","highestDevelopmentStatusID":"11","companyTruncated":"Biotechnology Institute IMASD \/ Hospital de Basurto"},{"orgOrder":0,"company":"Helixmith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Engensis","moa":"HGF receptor","graph1":"Podiatry","graph2":"Phase III","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helixmith \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Helixmith \/ Undisclosed"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioStem Technologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Undisclosed"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioStem Technologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Skingenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Sesame Oil","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Skingenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Skingenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skingenix \/ Undisclosed"},{"orgOrder":0,"company":"Skingenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Sesame Oil","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Skingenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Skingenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skingenix \/ Undisclosed"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AUP1602-C","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Aurealis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Aurealis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aurealis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AUP1602-C","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Aurealis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Aurealis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aurealis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ON101","moa":"Immune","graph1":"Podiatry","graph2":"Phase III","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ON101","moa":"Immune","graph1":"Podiatry","graph2":"Phase III","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ON101","moa":"Immune","graph1":"Podiatry","graph2":"Phase III","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Srinakharinwirot University","sponsor":"Oxo Chemie | Altermed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"THAILAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"WF10","moa":"Immune","graph1":"Podiatry","graph2":"Phase II","graph3":"Srinakharinwirot University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Srinakharinwirot University \/ Oxo Chemie | Altermed","highestDevelopmentStatusID":"8","companyTruncated":"Srinakharinwirot University \/ Oxo Chemie | Altermed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Polish Stem Cells Bank","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"POLAND","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Allogeneic Adsc Stem Cell","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Medical University of Warsaw \/ Polish Stem Cells Bank","highestDevelopmentStatusID":"7","companyTruncated":"Medical University of Warsaw \/ Polish Stem Cells Bank"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Podiatry","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tapentadol","moa":"Mu opioid receptor | Norepinephrine transporter","graph1":"Podiatry","graph2":"Phase II","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Grunenthal \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Grunenthal \/ Undisclosed"},{"orgOrder":0,"company":"Cali Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CPL-01","moa":"Na channel-alpha-subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Cali Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cali Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cali Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cali Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CPL-01","moa":"Na channel-alpha-subunit","graph1":"Podiatry","graph2":"Phase II","graph3":"Cali Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cali Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cali Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ITALY","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Tapentadol","moa":"Norepinephrine transporter","graph1":"Podiatry","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Grunenthal"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Tapentadol","moa":"Norepinephrine transporter","graph1":"Podiatry","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Virchow Group","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Biochaperone Pdgf-Bb","moa":"PDGF","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Virchow Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Virchow Group \/ Adocia","highestDevelopmentStatusID":"7","companyTruncated":"Virchow Group \/ Adocia"},{"orgOrder":0,"company":"Adocia","sponsor":"Virchow Group","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Biochaperone Pdgf-Bb","moa":"PDGF","graph1":"Podiatry","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Virchow Group","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Virchow Group"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"DSC127","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Integra LifeSciences \/ Integrium","highestDevelopmentStatusID":"10","companyTruncated":"Integra LifeSciences \/ Integrium"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"DSC127","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Integrium","highestDevelopmentStatusID":"10","companyTruncated":"Integra LifeSciences \/ Integrium"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"DSC127","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Integrium","highestDevelopmentStatusID":"10","companyTruncated":"Integra LifeSciences \/ Integrium"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Granexin","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Xequel Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xequel Bio \/ Undisclosed"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Medical University of South Carolina | Spartanburg Regional Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Granexin","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Xequel Bio \/ Medical University of South Carolina | Spartanburg Regional Healthcare System","highestDevelopmentStatusID":"10","companyTruncated":"Xequel Bio \/ Medical University of South Carolina | Spartanburg Regional Healthcare System"},{"orgOrder":0,"company":"University of Mississippi Medical Center","sponsor":"Keystone Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Podiatry","graph2":"Phase I","graph3":"University of Mississippi Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Mississippi Medical Center \/ Keystone Pharmacy","highestDevelopmentStatusID":"6","companyTruncated":"University of Mississippi Medical Center \/ Keystone Pharmacy"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Lynch Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Peptide, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Becaplermin","moa":"Platelet-derived growth factor receptor","graph1":"Podiatry","graph2":"Approved FDF","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"SMITH & NEPHEW INC \/ Lynch Regenerative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"SMITH & NEPHEW INC \/ Lynch Regenerative Medicine"},{"orgOrder":0,"company":"Cell2Cure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"DENMARK","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Adipose Tissue Derived Mesenchymal Stromal\/Stem Cell","moa":"Progenitor cell","graph1":"Podiatry","graph2":"Phase I","graph3":"Cell2Cure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cell2Cure \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cell2Cure \/ Undisclosed"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"LifeNet Health","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Dermacell","moa":"Progenitor cell","graph1":"Podiatry","graph2":"Phase II\/ Phase III","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ LifeNet Health","highestDevelopmentStatusID":"9","companyTruncated":"Baylor College of Medicine \/ LifeNet Health"},{"orgOrder":0,"company":"PluroGen Therapeutics","sponsor":"Arkios BioDevelopment International","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Plurogel N","moa":"Skin barrier","graph1":"Podiatry","graph2":"Phase II","graph3":"PluroGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"PluroGen Therapeutics \/ Arkios BioDevelopment International","highestDevelopmentStatusID":"8","companyTruncated":"PluroGen Therapeutics \/ Arkios BioDevelopment International"},{"orgOrder":0,"company":"PluroGen Therapeutics","sponsor":"Arkios BioDevelopment International","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Plurogel Pn","moa":"Skin barrier","graph1":"Podiatry","graph2":"Phase II","graph3":"PluroGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"PluroGen Therapeutics \/ Arkios BioDevelopment International","highestDevelopmentStatusID":"8","companyTruncated":"PluroGen Therapeutics \/ Arkios BioDevelopment International"},{"orgOrder":0,"company":"Rothman Institute","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Podiatry","graph2":"Phase IV","graph3":"Rothman Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rothman Institute \/ Merz Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Rothman Institute \/ Merz Therapeutics"},{"orgOrder":0,"company":"Omeza","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Podiatry","graph2":"Phase I","graph3":"Omeza","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeza \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Omeza \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Podiatry","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"PainReform","sponsor":"Lotus Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"PainReform","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PainReform \/ Lotus Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"PainReform \/ Lotus Clinical Research"},{"orgOrder":0,"company":"OhioHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Podiatry","graph2":"Undisclosed","graph3":"OhioHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OhioHealth \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"OhioHealth \/ Undisclosed"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"local anesthetics||Sodium channel alpha subunit","graph1":"Podiatry","graph2":"Phase II","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiwan Liposome Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiwan Liposome Company \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Catherine Vandepitte","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase II","graph3":"Catherine Vandepitte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catherine Vandepitte \/ Pacira BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"Catherine Vandepitte \/ Pacira BioSciences"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"UTTR1147A","moa":"TGF-beta","graph1":"Podiatry","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"University of Guadalajara","sponsor":"Cell Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"MEXICO","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"University of Guadalajara","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"University of Guadalajara \/ Cell Pharma","highestDevelopmentStatusID":"7","companyTruncated":"University of Guadalajara \/ Cell Pharma"},{"orgOrder":0,"company":"Centrexion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CTNX-4975","moa":"TRPV1","graph1":"Podiatry","graph2":"Phase I","graph3":"Centrexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centrexion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Centrexion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vocacapsaicin","moa":"TRPV1","graph1":"Podiatry","graph2":"Phase I","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concentric Analgesics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Concentric Analgesics \/ Undisclosed"},{"orgOrder":0,"company":"Aposcience","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"APO-2","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Aposcience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Aposcience \/ FGK Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Aposcience \/ FGK Clinical Research"},{"orgOrder":0,"company":"Charsire Biotechnology","sponsor":"ASKLEP Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"CSTC1","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Charsire Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charsire Biotechnology \/ ASKLEP Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Charsire Biotechnology \/ ASKLEP Inc."},{"orgOrder":0,"company":"Transwell Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"TWB-103","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Transwell Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Transwell Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Transwell Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Supergenics Life Science Sdn. Bhd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"MALAYSIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Supergenics Life Science Sdn. Bhd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Supergenics Life Science Sdn. Bhd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Supergenics Life Science Sdn. Bhd. \/ Undisclosed"},{"orgOrder":0,"company":"New Horizon Medical Solutions","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Amnio Matrix","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"New Horizon Medical Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New Horizon Medical Solutions \/ Amarex Clinical Research","highestDevelopmentStatusID":"1","companyTruncated":"New Horizon Medical Solutions \/ Amarex Clinical Research"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Amniotic Chorion Tissue Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioStem Technologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu ProteLight Pharmaceutical & Biotechnology","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Antimicrobial Peptide PL-5","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Jiangsu ProteLight Pharmaceutical & Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Jiangsu ProteLight Pharmaceutical & Biotechnology \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu ProteLight Pharmaceutical & Biotechnology \/ Parexel"},{"orgOrder":0,"company":"Shanghai East Hospital","sponsor":"Faendrich Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Autoregulatory Monocyte","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Shanghai East Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai East Hospital \/ Faendrich Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai East Hospital \/ Faendrich Biotechnology"},{"orgOrder":0,"company":"Blue Blood Biotech Corp.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BB-101","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Blue Blood Biotech Corp.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Blood Biotech Corp. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blue Blood Biotech Corp. \/ Undisclosed"},{"orgOrder":0,"company":"Blue Blood Biotech Corp.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BB-101","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Blue Blood Biotech Corp.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Blood Biotech Corp. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blue Blood Biotech Corp. \/ Undisclosed"},{"orgOrder":0,"company":"Osiris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CHAM","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Osiris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osiris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Osiris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Comac Medical","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ITALY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CHF6467","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Comac Medical","highestDevelopmentStatusID":"7","companyTruncated":"Chiesi Group \/ Comac Medical"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Cynata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Cynata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Cynata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Cynata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CYP-006TK","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Cynata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"FibroBiologics","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Collaboration","leadProduct":"CYWC628","moa":"Undisclosed","graph1":"Podiatry","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ FibroBiologics","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ FibroBiologics"},{"orgOrder":0,"company":"MiMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Dehydrated Human Amnion Chorion Membrane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"MiMedx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MiMedx \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Diamel","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Diperoxochloric Acid","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Centaur Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centaur Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Centaur Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SerenaGroup, Inc.","sponsor":"Tides Medical","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DLAM","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase IV","graph3":"SerenaGroup, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SerenaGroup, Inc. \/ Tides Medical","highestDevelopmentStatusID":"11","companyTruncated":"SerenaGroup, Inc. \/ Tides Medical"},{"orgOrder":0,"company":"Changi General Hospital","sponsor":"ELO Water Pte. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SINGAPORE","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Elo Water","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"Changi General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changi General Hospital \/ ELO Water Pte. Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Changi General Hospital \/ ELO Water Pte. Ltd."},{"orgOrder":0,"company":"Energenesis Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ENERGI-F703","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Energenesis Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Energenesis Biomedical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Energenesis Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Energenesis Biomedical","sponsor":"A2 Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ENERGI-F703","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Energenesis Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Energenesis Biomedical \/ A2 Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Energenesis Biomedical \/ A2 Healthcare"},{"orgOrder":0,"company":"Cathay General Hospital","sponsor":"Oneness Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fespixon","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase IV","graph3":"Cathay General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cathay General Hospital \/ Oneness Biotech","highestDevelopmentStatusID":"11","companyTruncated":"Cathay General Hospital \/ Oneness Biotech"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"China Medical University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fespixon","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase IV","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Oneness Biotech \/ China Medical University Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Oneness Biotech \/ China Medical University Hospital"},{"orgOrder":0,"company":"Joseph Boykin, MD","sponsor":"George Mason University | Central Arkansas Veterans Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Folinic Acid Calcium Salt","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Joseph Boykin, MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joseph Boykin, MD \/ George Mason University | Central Arkansas Veterans Healthcare System","highestDevelopmentStatusID":"8","companyTruncated":"Joseph Boykin, MD \/ George Mason University | Central Arkansas Veterans Healthcare System"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Osiris Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Grafixpl Prime","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Osiris Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Osiris Therapeutics"},{"orgOrder":0,"company":"Cytora","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"hOMSC200","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cytora","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytora \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cytora \/ Undisclosed"},{"orgOrder":0,"company":"Liventa Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Human Allograft Amniotic Membrane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase IV","graph3":"Liventa Bioscience","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liventa Bioscience \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Liventa Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"MiMedx","sponsor":"Gunze Medical Limited","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Human Amnion Membrane Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiMedx \/ Gunze Medical Limited","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Gunze Medical Limited"},{"orgOrder":0,"company":"MiMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Amnion Membrane Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiMedx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Undisclosed"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"Shandong Qilu Stem Cells Engineering Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Cord Blood Mononuclear Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ Shandong Qilu Stem Cells Engineering Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ Shandong Qilu Stem Cells Engineering Co., Ltd."},{"orgOrder":0,"company":"MiMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Human Umbilical Cord Blood Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiMedx \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"MiMedx \/ Undisclosed"},{"orgOrder":0,"company":"Izun Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"IZN-6D4","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Izun Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Izun Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Izun Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lavior Pharma Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Lavior","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II\/ Phase III","graph3":"Lavior Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Lavior Pharma Inc. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lavior Pharma Inc. \/ Undisclosed"},{"orgOrder":0,"company":"OcuNexus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Oligonucleotide","year":"2011","type":"Inapplicable","leadProduct":"Lufepirsen","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"OcuNexus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OcuNexus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuNexus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Marine Collagen Peptides","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Microbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"MBN-101","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Microbion \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MDI-1228","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NGI226","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NOxy Health Products","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NOX1416","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"NOxy Health Products","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NOxy Health Products \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NOxy Health Products \/ Undisclosed"},{"orgOrder":0,"company":"NOxy Health Products","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NOX1416","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"NOxy Health Products","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NOxy Health Products \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NOxy Health Products \/ Undisclosed"},{"orgOrder":0,"company":"Celularity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"PDA-002","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Undisclosed"},{"orgOrder":0,"company":"European Egyptian Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"EGYPT","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Pedyphar","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"European Egyptian Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"European Egyptian Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"European Egyptian Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Rion","sponsor":"Professional Education and Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Pep Purified Exosome Product","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Rion \/ Professional Education and Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Professional Education and Research Institute"},{"orgOrder":0,"company":"Vitruvian Medical Devices, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Plasma","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Vitruvian Medical Devices, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Vitruvian Medical Devices, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vitruvian Medical Devices, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Microbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Microbion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Undisclosed"},{"orgOrder":0,"company":"Microbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Microbion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Undisclosed"},{"orgOrder":0,"company":"Microbion","sponsor":"US Navy","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Microbion \/ US Navy","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ US Navy"},{"orgOrder":0,"company":"Microbion","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0.02,"dosageForm":"Suspension","sponsorNew":"Microbion \/ CARB-X","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ CARB-X"},{"orgOrder":0,"company":"Microbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Microbion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Undisclosed"},{"orgOrder":0,"company":"Microbion","sponsor":"CUBRC | National Medical Research Council, Singapore | MTEC","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbion \/ CUBRC | National Medical Research Council, Singapore | MTEC","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ CUBRC | National Medical Research Council, Singapore | MTEC"},{"orgOrder":0,"company":"The VA Western New York Healthcare System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Procenta","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"The VA Western New York Healthcare System","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"The VA Western New York Healthcare System \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"The VA Western New York Healthcare System \/ Undisclosed"},{"orgOrder":0,"company":"Rion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Purified Exosome Product","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Rion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Discovery Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Discovery Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Discovery Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Discovery Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lynch Biologics","sponsor":"Medelis | Centro M\u00e9dico Militar","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Recombinant Human PDGF-BB","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Lynch Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lynch Biologics \/ Medelis | Centro M\u00e9dico Militar","highestDevelopmentStatusID":"8","companyTruncated":"Lynch Biologics \/ Medelis | Centro M\u00e9dico Militar"},{"orgOrder":0,"company":"European Egyptian Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"EGYPT","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Royal Jelly","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"European Egyptian Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"European Egyptian Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"European Egyptian Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Alira Health","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Skinte","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolarityTE \/ Alira Health","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Alira Health"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Professional Education and Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Skinte","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolarityTE \/ Professional Education and Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Professional Education and Research Institute"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"SkinTE","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolarityTE \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Undisclosed"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SPAIN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Tendoactive","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bioiberica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bioiberica \/ Undisclosed"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"TTAX01","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTissue Holdings \/ Undisclosed"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"TTAX01","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTissue Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Amniox Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"TTAX01","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Amniox Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amniox Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amniox Medical \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"WH-1","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Xianglei Tangzu Gao","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II\/ Phase III","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"GWT-TUD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"GERMANY","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Urokinase","moa":"Urokinase-type plasminogen activator","graph1":"Podiatry","graph2":"Phase III","graph3":"GWT-TUD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GWT-TUD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GWT-TUD \/ Undisclosed"},{"orgOrder":0,"company":"Centrexion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Podiatry","graph2":"Phase II","graph3":"Centrexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centrexion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centrexion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Centrexion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Podiatry","graph2":"Phase II","graph3":"Centrexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centrexion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centrexion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eluciderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ELU42","moa":"Wnt signalling pathway","graph1":"Podiatry","graph2":"IND Enabling","graph3":"Eluciderm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eluciderm \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Eluciderm \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de N\u00eemes","sponsor":"Phaxiam Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Centre Hospitalier Universitaire de N\u00eemes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Centre Hospitalier Universitaire de N\u00eemes \/ Phaxiam Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Centre Hospitalier Universitaire de N\u00eemes \/ Phaxiam Therapeutics"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Prisma Health-Upstate \/ Undisclosed"},{"orgOrder":0,"company":"Rion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Undisclosed"},{"orgOrder":0,"company":"FibroBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"FibroBiologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroBiologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FibroBiologics \/ Undisclosed"},{"orgOrder":0,"company":"HealthTech Wound Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DermaBind TL","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"HealthTech Wound Care","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HealthTech Wound Care \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HealthTech Wound Care \/ Undisclosed"},{"orgOrder":0,"company":"Royal Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase IV","graph3":"Royal Biologics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal Biologics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Royal Biologics \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bioiberica

                            Spain
                            Aquaexpo
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.

                            Lead Product(s) : Tendoactive

                            Therapeutic Area : Podiatry

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Efficacy of Tendoactive, Eccentric Training, and the Combination of Both as a Treatment of Achilles Tendin...

                            Details : Tendoactive is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Achilles Tendinitis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 25, 2012

                            Lead Product(s) : Tendoactive

                            Therapeutic Area : Podiatry

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Bioiberica Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Royal Biologics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Royal Biologics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Podiatry

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.

                            Details : This drug candidate is currently being evaluated in Phase IV clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 07, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HealthTech Wound Care

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            HealthTech Wound Care

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DermaBind TL

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL

                            Details : DermaBind TL is a Large Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 15, 2025

                            Lead Product(s) : DermaBind TL

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            New Horizon Medical Solutions

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            New Horizon Medical Solutions

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amnio Matrix

                            Therapeutic Area : Podiatry

                            Study Phase : Undisclosed

                            Sponsor : Amarex Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xcell Amnio Matrix (XAM) Safety and Efficacy In Various Wound Types

                            Details : Amnio Matrix is a Cell and Gene therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 11, 2025

                            Lead Product(s) : Amnio Matrix

                            Therapeutic Area : Podiatry

                            Highest Development Status : Undisclosed

                            Sponsor : Amarex Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            FibroBiologics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            FibroBiologics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CYWC628 (Fibroblast Spheroids) Safety & Efficacy In Refractory Diabetic Foot Ulcers vs SOC

                            Details : This drug candidate is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 31, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eluciderm

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Eluciderm

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELU42

                            Therapeutic Area : Podiatry

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eluciderm, Inc. Announces U.S. FDA Clearance of IND Application for ELU42

                            Details : ELU42 is a novel, topical, small molecule Wnt modulator with bacteriostatic properties for the treatment of chronic open wounds.

                            Product Name : ELU42

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 08, 2025

                            Lead Product(s) : ELU42

                            Therapeutic Area : Podiatry

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Biotechnology Institute IMASD

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Biotechnology Institute IMASD

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plasma Rich In Growth Factors

                            Therapeutic Area : Podiatry

                            Study Phase : Phase IV

                            Sponsor : Hospital de Basurto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Per...

                            Details : Plasma Rich In Growth Factors is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 01, 2025

                            Lead Product(s) : Plasma Rich In Growth Factors

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase IV

                            Sponsor : Hospital de Basurto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recce Gets Approval for New Phase 2 Trial of RECCE 327 Topical Gel

                            Details : RECCE 327 (R327) is a novel topical Bacterial ATP production inhibitor which is under development for the treatment of diabetic foot infections.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 23, 2025

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed

                            Recce Pharmaceuticals

                            Australia arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $15.8 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Recce Launches A$10.8M Entitlement Offer After A$5M Placement

                            Details : The proceeds from the placement will used for the clinical development of RECCE 327 (R327), which is being evaluated for the treatment of Diabetic Foot Infections.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            April 10, 2025

                            Lead Product(s) : R327

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $15.8 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            SMITH & NEPHEW INC

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            SMITH & NEPHEW INC

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Becaplermin

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Lynch Regenerative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lynch Regenerative Acquires REGRANEX® Gel for Soft Tissue Regeneration

                            Details : Under the acquisition, Lynch holds the exclusive rights to Regranex (becaplermin) gel and recombinant purified platelet-derived growth factor (PDGF). It is being indicated for diabetic foot ulcer.

                            Product Name : Regranex

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            March 31, 2025

                            Lead Product(s) : Becaplermin

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Lynch Regenerative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth